CTXR Citius Pharmaceuticals Inc.

0.94
-0.04  -4%
Previous Close 0.98
Open 1
Price To Book 0.97
Market Cap 20,751,234
Shares 22,075,781
Volume 44,287
Short Ratio
Av. Daily Volume 102,659

NewsSee all news

  1. Citius Announces Change To Primary Endpoint In Mino-Lok® Phase 3 Study

    CRANFORD, N.J., Sept. 4, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ:CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug

  2. Citius Pharmaceuticals, Inc. to Present at the RHK Capital 4th annual Disruptive Growth Conference hosted by Reed Smith.

    CRANFORD, N.J., Aug. 29, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (NASDAQ:CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 interim analysis 4Q 2019.
Mino-Lok
Catheter related blood stream infection
Phase 2b trial planned.
CITI-002
Hemorrhoids

Latest News

  1. Citius Announces Change To Primary Endpoint In Mino-Lok® Phase 3 Study

    CRANFORD, N.J., Sept. 4, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ:CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug

  2. Citius Pharmaceuticals, Inc. to Present at the RHK Capital 4th annual Disruptive Growth Conference hosted by Reed Smith.

    CRANFORD, N.J., Aug. 29, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (NASDAQ:CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced